Abstract Library

#3080 Impact of Multimodal Perioperative Treatment in Patients with Resected Non-Metastatic Grade 3 Neuroendocrine Neoplasms (NEN G3)

Introduction: Patients with grade 3 neuroendocrine neoplasm (NEN G3) have a limited prognosis. Even in a non-metastatic stage, the risk of recurrence after surgery is high. Multimodal perioperative treatment, including chemotherapy and/or radiotherapy in an adjuvant or neoadjuvant setting, has improved the prognosis in numerous tumor entities; however, it has not been systematically evaluated in NEN G3 so far. Nevertheless, perioperative chemotherapy is generally recommended in most current treatment guidelines for NEN G3.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Apostolidis L, Starke H, Bhatti I, Jäger D, Winkler E,

Keywords: NEN G3, neuroendocrine carcinoma, adjuvant, neoadjuvant, surgery,

#3079 Novel Symptoms and Therapy of Multiple Endocrine Neoplasia Type 1

Introduction: MEN1 is a rare autosomal inherited disease with hallmark of hyperparathyroidism, duodenopancreatic NENs and pituitary tumor.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: bai J

Authors: Bai J, Tang Q,

Keywords: MEN1, LGCS, NENs, gastrinoma, Parathyroid carcinoma,

#3076 Endometrial Small Cell Neuroendocrine Carcinoma: Case Report and Literature Review

Introduction: Endometrial small-cell neuroendocrine carcinoma (ESCNEC) is extremely rare. It is characterized by early regional and systemic spread leading to rapid development of lymph nodes, pelvic and extrapelvic metastasis and compromising the outcome.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Aris H, Ghomari S,

Keywords: endometrial small cell neuroendocrine carcinoma, surgery, adjuvant chemotherapy, brachytherapy,

#3075 Telotristat Makes Significant Difference on Symptoms and Serotonin Levels in a Population with Widespread GI-NET and Severe Carcinoid Syndrome

Introduction: In spite of new treatments like PRRT or everolimus there is a clinical need for systemic therapies that complement SSAs (somatostatin analogs) and antidiarrheal agents in the treatment of carcinoid syndrome, a late stage problem in s-i-NET. Telotristat is a promising addition to our therapeutic arsenal.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Linder Ekberg K,

Keywords: telotristat, carcinoid syndrome, metastasized GI-NET,

#3069 Functioning Pancreatic Neuroendocrine Tumors (F-pNETs): The Experience of a Tertiary Care Center of Pancreatic Surgery

Introduction: Surgery represents the optimal treatment of F-pNETs, especially if performed in high volume centers of pancreatic surgery.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Nessi C, Lenzi S, Landoni L, Bianchi B, Elio G,

Keywords: Functioning pancreatic neuroendocrine tumors, pancreatic surgery,